Dr. Shah has an active research program studying various aspects of scleroderma and Raynaud’s phenomenon. She is investigating the connection between cancer and scleroderma, as her early data suggest cancer may drive the development of scleroderma in some patients. She also conducts epidemiological studies and participates in clinical trials to examine 1) methods to detect cardiopulmonary complications in scleroderma, 2) biological and imaging markers of Raynaud’s severity and 3) drugs that may improve various aspects of the disease (such as skin, lung or vascular complications).
Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L. Close Temporal Relationship Between Onset of Cancer and Scleroderma in Patients with RNA Polymerase I/III Antibodies. Arthritis Rheum. 2010 Sep; 62(9): 2787-95. PMID: 20506513
Shah AA, Rosen A. Cancer and Systemic Sclerosis: Novel Insights into Pathogenesis and Clinical Implications. Curr Opin Rheumatol. 2011 Nov; 23(6): 530-5. PMID: 21825998.
Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I, Jiao Y, Papadopoulos N, Kinzler KW, Vogelstein B, Rosen A. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014 Jan 10;343(6167):152-7. PMID: 24310608.
Moinzadeh P, Fonseca C, Hellmich M, Shah AA, Chighizola C, Denton CP, Ong VH. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Research & Therapy. 2014 Feb 14;16(1):R53 [Epub ahead of print]. PMID: 24524733.
Shah AA, Casciola-Rosen L, Rosen A. Cancer-induced Autoimmunity in the Rheumatic Diseases. Arthritis Rheumatol. 2015 Feb;67(2):317-26. PMID: 25371098.
Shah AA, Hummers LK, Casciola-Rosen L, Visvanathan K, Rosen A, Wigley FM. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol. 2015 Apr;67(4):1053-61. PMID: 25605296.
Shah AA, Casciola-Rosen L. Cancer and Scleroderma: A Paraneoplastic Disease with Implications for Malignancy Screening. Curr Opin Rheumatol. 2015, in press.